Bioenhanced advanced third generation solid dispersion of tadalafil: Repurposing with improved therapy in pyelonephritis

Tadalafil (TDL) a BCS-II drug is recently reported for repurposing nephroprotective effect in Pyelonephritis (PN). However, poor water solubility and dissolution rate limited oral bioavailability pose serious challenges in its therapeutic applications. We present an advanced third generation Solid D...

Full description

Bibliographic Details
Main Authors: Prashant P. Mande, Sagar S. Bachhav, Padma V. Devarajan
Format: Article
Language:English
Published: Elsevier 2017-11-01
Series:Asian Journal of Pharmaceutical Sciences
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1818087617300739
id doaj-36cfae8e16ee435a9c629736be7874cc
record_format Article
spelling doaj-36cfae8e16ee435a9c629736be7874cc2020-11-24T23:24:00ZengElsevierAsian Journal of Pharmaceutical Sciences1818-08762017-11-0112656957910.1016/j.ajps.2017.07.001Bioenhanced advanced third generation solid dispersion of tadalafil: Repurposing with improved therapy in pyelonephritisPrashant P. MandeSagar S. BachhavPadma V. DevarajanTadalafil (TDL) a BCS-II drug is recently reported for repurposing nephroprotective effect in Pyelonephritis (PN). However, poor water solubility and dissolution rate limited oral bioavailability pose serious challenges in its therapeutic applications. We present an advanced third generation Solid Dispersion (SD) of TDL comprising a polymer in combination with a Self Micro-emulsifying Composition (SMEC) to achieve high drug loading, improved stability and rapid dissolution of TDL for enhancing bioavailability and efficacy in PN. TDL-SMEC-SD was coated onto rapidly disintegrating inert tablet cores which disintegrated rapidly in water to release SD as a film. TDL-SMEC-SD was evaluated for in-vivo oral bioavailability and in-vivo efficacy in lipopolysaccharide-induced PN in rats. TDL exhibited high solubility (45.6 mg/ml) in the SMEC. TDL-SMEC-SD exhibited remarkably high TDL loading (45%w/w), exceptionally low contact angle (9°), rapid in-vitro release (t50 7.3 min), microemulsion formation (globule size ~100 nm) in aqueous dispersion, and stability as per ICH guidelines. SEM, DSC, and XRD confirmed high physical stability. A relative bioavailability of 350% and 150% compared to TDL and TDL-SD without SMEC respectively, established the superiority of TDL-SMEC-SD. A significant reduction in serum creatinine, blood urea nitrogen and nitric oxide levels in the lipopolysaccharide-induced PN confirmed the benefit of the TDL-SMEC-SD. The advanced third generation SMEC SDs presents the possibility of platform technology for bioenhancement of poorly water soluble drugs.http://www.sciencedirect.com/science/article/pii/S1818087617300739Phosphodiesterase-5LipopolysaccharideKidney infectionEudragit EPOKidney failure
collection DOAJ
language English
format Article
sources DOAJ
author Prashant P. Mande
Sagar S. Bachhav
Padma V. Devarajan
spellingShingle Prashant P. Mande
Sagar S. Bachhav
Padma V. Devarajan
Bioenhanced advanced third generation solid dispersion of tadalafil: Repurposing with improved therapy in pyelonephritis
Asian Journal of Pharmaceutical Sciences
Phosphodiesterase-5
Lipopolysaccharide
Kidney infection
Eudragit EPO
Kidney failure
author_facet Prashant P. Mande
Sagar S. Bachhav
Padma V. Devarajan
author_sort Prashant P. Mande
title Bioenhanced advanced third generation solid dispersion of tadalafil: Repurposing with improved therapy in pyelonephritis
title_short Bioenhanced advanced third generation solid dispersion of tadalafil: Repurposing with improved therapy in pyelonephritis
title_full Bioenhanced advanced third generation solid dispersion of tadalafil: Repurposing with improved therapy in pyelonephritis
title_fullStr Bioenhanced advanced third generation solid dispersion of tadalafil: Repurposing with improved therapy in pyelonephritis
title_full_unstemmed Bioenhanced advanced third generation solid dispersion of tadalafil: Repurposing with improved therapy in pyelonephritis
title_sort bioenhanced advanced third generation solid dispersion of tadalafil: repurposing with improved therapy in pyelonephritis
publisher Elsevier
series Asian Journal of Pharmaceutical Sciences
issn 1818-0876
publishDate 2017-11-01
description Tadalafil (TDL) a BCS-II drug is recently reported for repurposing nephroprotective effect in Pyelonephritis (PN). However, poor water solubility and dissolution rate limited oral bioavailability pose serious challenges in its therapeutic applications. We present an advanced third generation Solid Dispersion (SD) of TDL comprising a polymer in combination with a Self Micro-emulsifying Composition (SMEC) to achieve high drug loading, improved stability and rapid dissolution of TDL for enhancing bioavailability and efficacy in PN. TDL-SMEC-SD was coated onto rapidly disintegrating inert tablet cores which disintegrated rapidly in water to release SD as a film. TDL-SMEC-SD was evaluated for in-vivo oral bioavailability and in-vivo efficacy in lipopolysaccharide-induced PN in rats. TDL exhibited high solubility (45.6 mg/ml) in the SMEC. TDL-SMEC-SD exhibited remarkably high TDL loading (45%w/w), exceptionally low contact angle (9°), rapid in-vitro release (t50 7.3 min), microemulsion formation (globule size ~100 nm) in aqueous dispersion, and stability as per ICH guidelines. SEM, DSC, and XRD confirmed high physical stability. A relative bioavailability of 350% and 150% compared to TDL and TDL-SD without SMEC respectively, established the superiority of TDL-SMEC-SD. A significant reduction in serum creatinine, blood urea nitrogen and nitric oxide levels in the lipopolysaccharide-induced PN confirmed the benefit of the TDL-SMEC-SD. The advanced third generation SMEC SDs presents the possibility of platform technology for bioenhancement of poorly water soluble drugs.
topic Phosphodiesterase-5
Lipopolysaccharide
Kidney infection
Eudragit EPO
Kidney failure
url http://www.sciencedirect.com/science/article/pii/S1818087617300739
work_keys_str_mv AT prashantpmande bioenhancedadvancedthirdgenerationsoliddispersionoftadalafilrepurposingwithimprovedtherapyinpyelonephritis
AT sagarsbachhav bioenhancedadvancedthirdgenerationsoliddispersionoftadalafilrepurposingwithimprovedtherapyinpyelonephritis
AT padmavdevarajan bioenhancedadvancedthirdgenerationsoliddispersionoftadalafilrepurposingwithimprovedtherapyinpyelonephritis
_version_ 1725562477337378816